NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
Travera Inc
Medical University of Graz
Beijing Kejing Biotechnology Co., Ltd.
Massachusetts General Hospital